Answers are grounded in this paper and cite their sources.
Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines
No takes yet. Share an insight, caveat, or question.
Rid et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: